The price per share for the offering, which closed yesterday, was equivalent to the five-day volume-weighted average share price at $12.5658 apiece, Hayward, Calif.-based Pulse said.
The company received subscriptions and over-subscriptions for 4,023,779 shares, topping the original offering of 3,581,148 shares.
“We are pleased with the results of the rights offering,” president & CEO Darrin Uecker said in prepared remarks. “The rights offering offered our stockholders an opportunity to participate in this important financing that will enable us to continue progress towards our goal of commercializing our proprietary CellFX Nano-Pulse Stimulation platform, initially in aesthetic dermatology. We remain committed to building a viable company and to stockholder value, and look forward to updating you on our progress as we continue to generate important results in the future.”
PLSE shares were trading at $12.82 today in mid-day trading, up 2.9%.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.